Association between body mass index, weight loss and the chance of pregnancy in women with polycystic ovary syndrome and overweight or obesity: a retrospective cohort study in the UK.
BMI
cohort study
fecundity
obesity
overweight
polycystic ovary syndrome
pregnancy
weight loss
Journal
Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
18
08
2022
revised:
29
11
2022
pubmed:
14
1
2023
medline:
4
3
2023
entrez:
13
1
2023
Statut:
ppublish
Résumé
What are the associations between baseline BMI (Study 1) and change in body weight (Study 2) with the likelihood of pregnancy in women with polycystic ovary syndrome (PCOS). In women with PCOS, higher baseline BMI was associated with a lower chance of pregnancy; however, weight loss was associated with an increased chance of pregnancy versus maintaining a stable weight or gaining weight. Two studies in large cohorts of Danish women with the intention to become pregnant showed a decline in fecundability ratios with higher BMI. Furthermore, a meta-analysis found that overweight/obesity significantly worsened metabolic and reproductive outcomes in women with PCOS. Data were extracted from the UK Clinical Practice Research Datalink GOLD database. Patients included women aged 18-45 years with BMI ≥18.5 (Study 1) or ≥25 kg/m2 (Study 2) at time of PCOS diagnosis (index date). The primary outcome was the time to first pregnancy recorded during 36-months' follow-up, analysed with Cox proportional hazard models and presented as hazard ratios (HRs). Study 1 included 9955 women with PCOS. Study 2 included 7593 women with PCOS and median BMI of 34.0 kg/m2. Higher BMI was associated with a lower chance of pregnancy in the 3 years following diagnosis. It was estimated that 41% of women with normal weight (18.5-24.9 kg/m2) would become pregnant compared to 17% of women with obesity class III (BMI ≥40.0 kg/m2) during follow-up. Furthermore, the chance of pregnancy for women with obesity class III was estimated to be 63% lower than for women with normal weight, with the same age and glycaemic status (HR 0.37, 95% CI 0.31-0.44; P < 0.0001). A significant inverse association was found between BMI change and chance of pregnancy: 10% weight loss was estimated to increase the chance of pregnancy by 68% for women with baseline BMI of 40 kg/m2 (HR 1.68, 95% CI 1.49-1.90). Multiple factors influence the chance of pregnancy (the ability and willingness to become pregnant), which was addressed by exclusion criteria employed. The real-world nature of the study means that use of non-prescription contraceptives was not available. Bias may have been introduced by the fact that only around 40% of women with PCOS in the CPRD GOLD database had their BMI recorded during the year prior to PCOS diagnosis. BMI categories used in the analyses may not be applicable to women of all ethnicities. The study population was only representative of women in the UK and results may not be generalizable to other regions. PCOS diagnoses were based on codes entered into the system by primary care providers, and no information was available regarding the criteria used for diagnosis, although symptoms used to diagnose PCOS have not changed over time. Our observations provide further evidence of the benefits of weight loss in women with overweight/obesity and PCOS who are seeking to become pregnant. Novo Nordisk A/S. A.H.B. declares fees for consultancy from Novo Nordisk. P.N.L. and C.L.H. are employees of Novo Nordisk. V.S. and A.V. are employees of, and hold shares in, Novo Nordisk. N/A.
Identifiants
pubmed: 36637246
pii: 6986989
doi: 10.1093/humrep/deac267
pmc: PMC9977115
doi:
Types de publication
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
471-481Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
Références
Life (Basel). 2022 Feb 18;12(2):
pubmed: 35207595
Reproduction. 2014 Jul;148(1):R15-27
pubmed: 24760880
Fertil Steril. 1995 Jul;64(1):22-8
pubmed: 7789569
Hum Reprod. 2004 Jan;19(1):41-7
pubmed: 14688154
Obes Rev. 2019 Jun;20(6):842-858
pubmed: 30785659
Expert Rev Endocrinol Metab. 2013 Jan;8(1):71-79
pubmed: 30731654
Hum Reprod Update. 2016 Nov;22(6):687-708
pubmed: 27511809
Hum Reprod. 2007 Jun;22(6):1634-7
pubmed: 17344224
Reprod Biol Endocrinol. 2018 Mar 9;16(1):22
pubmed: 29523133
Clin Med Insights Reprod Health. 2019 Sep 09;13:1179558119874042
pubmed: 31523137
Hum Reprod. 2006 Jan;21(1):80-9
pubmed: 16199429
Hum Reprod Update. 2018 Nov 1;24(6):694-709
pubmed: 30059968
Obes Rev. 2016 Mar;17(3):262-75
pubmed: 26663309
Fertil Steril. 2018 Aug;110(3):364-379
pubmed: 30033227
Hum Reprod. 2010 Jan;25(1):253-64
pubmed: 19828554
Fertil Steril. 2017 Apr;107(4):840-847
pubmed: 28292619
Semin Reprod Med. 2008 Jan;26(1):72-84
pubmed: 18181085
J Clin Endocrinol Metab. 2015 Nov;100(11):4048-58
pubmed: 26401593
Hum Reprod. 2019 Oct 2;34(10):2052-2060
pubmed: 31504532
Obes Rev. 2013 Feb;14(2):95-109
pubmed: 23114091
Endocr Connect. 2021 Oct 18;10(11):R267-R278
pubmed: 34559064
Development. 2015 Feb 15;142(4):681-91
pubmed: 25670793
BMJ. 2017 Feb 8;356:j1
pubmed: 28179267
J Clin Endocrinol Metab. 2016 Jul;101(7):2658-66
pubmed: 27172435
Obes Rev. 2019 May;20(5):659-674
pubmed: 30674081
Hum Reprod Update. 2004 May-Jun;10(3):267-80
pubmed: 15140873
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32442310
J Gynecol Obstet Hum Reprod. 2021 Jun;50(6):101894
pubmed: 32814159
Am J Obstet Gynecol. 2017 May;216(5):493.e1-493.e13
pubmed: 28104402
Hum Reprod Update. 2017 Nov 1;23(6):681-705
pubmed: 28961722
Hum Reprod. 2016 Dec;31(12):2841-2855
pubmed: 27664216